COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells

被引：0
|
作者：
Naoise C. Synnott
David O’Connell
John Crown
Michael J. Duffy
机构：
[1] University College Dublin,UCD School of Medicine, Conway Institute of Biomolecular and Biomedical Research
[2] University College Dublin,UCD School of Biomolecular & Biomedical Science
[3] St. Vincent’s University Hospital,Department of Medical Oncology
[4] St. Vincent’s University Hospital,UCD Clinical Research Centre
来源：
Breast Cancer Research and Treatment | 2020年 / 179卷
关键词：
p53; TP53; COTI-2; Triple-negative breast cancer; Treatment; APR-246;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：47 / 56
页数：9
相关论文
共 50 条
  • [31] p53 status identifies triple-negative breast cancer patients who do not respond to adjuvant chemotherapy
    Coradini, Danila
    Biganzoli, Elia
    Ardoino, Ilaria
    Ambrogi, Federico
    Boracchi, Patrizia
    Demicheli, Romano
    Daidone, Maria Grazia
    Moliterni, Angela
    BREAST, 2015, 24 (03) : 294 - 297
  • [32] Prognostic significance of p16 & p53 immunohistochemical expression in triple negative breast cancer
    Hashmi, Atif Ali
    Naz, Samreen
    Hashmi, Shumaila Kanwal
    Hussain, Zubaida Fida
    Irfan, Muhammad
    Khan, Erum Yousuf
    Faridi, Naveen
    Khan, Amir
    Edhi, Muhammad Muzzammil
    BMC CLINICAL PATHOLOGY, 2018, 18
  • [33] Association between p53 Expression and Amount of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer
    Lee, Miseon
    Park, In Ah
    Heo, Sun-Hee
    Kim, Young-Ae
    Gong, Gyungyub
    Lee, Hee Jin
    JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE, 2019, 53 (03) : 180 - 187
  • [34] The prognostic relevance of p53 and Ki-67 to chemotherapy sensitivity and prognosis in triple-negative breast cancer
    Zhang, Guojing
    Shi, Zhongyi
    Liu, Lina
    Yuan, Heqing
    Pan, Zheng
    Li, Wenxu
    Tao, Yu
    Huang, Zhaoming
    Huang, Xiaoying
    Lin, Chao
    TRANSLATIONAL CANCER RESEARCH, 2021, 10 (02) : 1082 - 1087
  • [35] p53 alteration in morphologically normal/benign breast tissue in patients with triple-negative high-grade breast carcinomas: breast p53 signature?
    Wang, Xi
    Stolla, Moritz
    Ring, Brian Z.
    Yang, Qi
    Laughlin, Todd S.
    Rothberg, Paul G.
    Skinner, Kristin
    Hicks, David G.
    HUMAN PATHOLOGY, 2016, 55 : 196 - 201
  • [36] Understanding the prion-like behavior of mutant p53 proteins in triple-negative breast cancer pathogenesis: The current therapeutic strategies and future directions
    Naeimzadeh, Yasaman
    Tajbakhsh, Amir
    Fallahi, Jafar
    HELIYON, 2024, 10 (04)
  • [37] p53 downregulates PD-L1 expression via miR-34a to inhibit the growth of triple-negative breast cancer cells: a potential clinical immunotherapeutic target
    Deng, Siyu
    Wang, Mengna
    Wang, Chenglong
    Zeng, Yan
    Qin, Xue
    Tan, Yiwen
    Liang, Bing
    Cao, Youde
    MOLECULAR BIOLOGY REPORTS, 2023, 50 (01) : 577 - 587
  • [38] Pharmacological Inhibition of MDM2 Induces Apoptosis in p53-Mutated Triple-Negative Breast Cancer
    On, Jasmin Linh
    Ghaderi, Sahel
    Rittmann, Carina
    Hoffmann, Greta
    Gier, Franziska
    Woloschin, Vitalij
    Tu, Jia-Wey
    Bhatia, Sanil
    Kulik, Andrea
    Niederacher, Dieter
    Neubauer, Hans
    Kurz, Thomas
    Fehm, Tanja
    Esser, Knud
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2025, 26 (03)
  • [39] Targeting LRP8 inhibits breast cancer stem cells in triple-negative breast cancer
    Lin, Chang-Ching
    Lo, Miao-Chia
    Moody, Rebecca
    Jiang, Hui
    Harouaka, Ramdane
    Stevers, Nicholas
    Tinsley, Samantha
    Gasparyan, Mari
    Wicha, Max
    Sun, Duxin
    CANCER LETTERS, 2018, 438 : 165 - 173
  • [40] p53 downregulates PD-L1 expression via miR-34a to inhibit the growth of triple-negative breast cancer cells: a potential clinical immunotherapeutic target
    Siyu Deng
    Mengna Wang
    Chenglong Wang
    Yan Zeng
    Xue Qin
    Yiwen Tan
    Bing Liang
    Youde Cao
    Molecular Biology Reports, 2023, 50 : 577 - 587
12345